Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial

Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahu, Ankit Kumar, Katheria, Arpita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424354/
https://www.ncbi.nlm.nih.gov/pubmed/34474770
http://dx.doi.org/10.1016/j.ihj.2021.06.019
_version_ 1783749657579487232
author Sahu, Ankit Kumar
Katheria, Arpita
author_facet Sahu, Ankit Kumar
Katheria, Arpita
author_sort Sahu, Ankit Kumar
collection PubMed
description Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a large trial where rivaroxaban was found to be non-inferior to warfarin on head-to-head basis. This commentary discusses the various aspects related to oral anticoagulation in bioprosthetic valve recipients in the light of recent clinical evidence.
format Online
Article
Text
id pubmed-8424354
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84243542021-09-13 Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial Sahu, Ankit Kumar Katheria, Arpita Indian Heart J Opinion Paper Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a large trial where rivaroxaban was found to be non-inferior to warfarin on head-to-head basis. This commentary discusses the various aspects related to oral anticoagulation in bioprosthetic valve recipients in the light of recent clinical evidence. Elsevier 2021 2021-07-01 /pmc/articles/PMC8424354/ /pubmed/34474770 http://dx.doi.org/10.1016/j.ihj.2021.06.019 Text en © 2021 Cardiological Society of India. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Opinion Paper
Sahu, Ankit Kumar
Katheria, Arpita
Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title_full Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title_fullStr Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title_full_unstemmed Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title_short Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
title_sort is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – new insights from river trial
topic Opinion Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424354/
https://www.ncbi.nlm.nih.gov/pubmed/34474770
http://dx.doi.org/10.1016/j.ihj.2021.06.019
work_keys_str_mv AT sahuankitkumar isthisthebeginningofendforwarfarininbioprostheticmitralvalverecipientswithatrialfibrillationnewinsightsfromrivertrial
AT katheriaarpita isthisthebeginningofendforwarfarininbioprostheticmitralvalverecipientswithatrialfibrillationnewinsightsfromrivertrial

Ejemplares similares